Publications

The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naïve HIV/HCV co-infected subjects

Non-immunosuppressive Cyclosporin Debio-025 with Interferon shows synergistic Anti-HCV Effect in Chimeric Mouse

Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT- 11) in advanced 5-FU-refractory colorectal cancer: MTD definition and efficacy…

Selective inhibitors of Hepatitis C virus replication

Postconditioning and Debio-025 Prevent LV Remodelling and Reduce Mortaility Following Acute Myocardial Infarction in Mice

Cyclosporine increases Human Immunodeficiency virus Type 1 Vector Transduction of Primary Mouse Cells

In Vivo and in Vitro Effects of Debio-025, a non-immunosuppressive Cyclosporin A Derivative on Duchene Muscular Dystrophy

Hepatoprotection by Cyclosporin A in Experimental Hepatitis. Sorting Desensitization of the Mitochondrial Permeablility Transition Pore from Immunosuppression

The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases